Syngene stock falls 10% after Q4 results – FY26 guidance gives investors a shock|
On 24 April 2025, Syngene International Ltd shares took a big shock – the stock fell 10% as the company announced its Q4 FY25 results. This was due to a 3% year-on-year decline in net profit, which
Quarterly and Annual Numbers:
Q4 FY25 Total Income: ₹1,037 crore (vs ₹933 crore last year)
Q4 FY25 Net Profit: ₹183 crore (vs ₹189 crore last year)
FY25 Full-Year Net Profit: ₹496 crore (vs ₹510 crore in FY24)
FY25 Total Income: ₹3,714 crore (vs ₹3,579 crore in FY24)
FY26 Guidance Has Doubled Investors’ Tension
The company’s CEO Deepak Jain said: “EBITDA margin will rise in mid 20s and profit after tax may decline year on year.” The market reacted immediately to this and brokerages also showed concern. According to CNBC Awaaz, a brokerage note wrote:
“In FY25, revenue growth was only 2% and 4% in INR terms. For FY26, management has guided mid-single digit growth, while the consensus was expecting 15% growth.”
Read More: Rohit did wonders, Boult-Chahar made a bow – Mumbai Indians’ tremendous victory over Sunrisers.
Global Challenges of Biotech Sector and Company’s Response
The biotech funding environment has been quite challenging at the global level, and its impact is also visible on Syngene. The company has taken some strategic initiatives such as U.S. I am acquiring a state of the art biologics manufacturing facility to boost my CDMO (Contract Development & Manufacturing Organization) business. If you wish to invest in Syngene or any other stock, please consult a certified financial advisor.
